QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
QQQ   290.94 (-1.80%)
AAPL   143.21 (-1.86%)
MSFT   242.76 (-2.18%)
META   147.56 (-2.75%)
GOOGL   97.09 (-2.29%)
AMZN   100.87 (-1.34%)
TSLA   169.59 (-4.67%)
NVDA   194.10 (-4.69%)
NIO   12.01 (-5.51%)
BABA   111.72 (-5.63%)
AMD   73.18 (-2.94%)
T   20.16 (+1.05%)
MU   62.15 (-2.69%)
F   12.93 (-2.56%)
CGC   2.88 (-1.71%)
GE   80.86 (-2.85%)
DIS   108.16 (-1.26%)
AMC   4.97 (-9.80%)
PFE   43.46 (-0.75%)
PYPL   80.41 (-1.74%)
NFLX   354.30 (-1.79%)
NASDAQ:CBAY

CymaBay Therapeutics - CBAY Stock Forecast, Price & News

$8.26
+0.46 (+5.90%)
(As of 01/30/2023 02:53 PM ET)
Add
Compare
Today's Range
$7.78
▼
$8.46
50-Day Range
$3.27
▼
$8.06
52-Week Range
$1.67
▼
$8.46
Volume
1.15 million shs
Average Volume
1.77 million shs
Market Capitalization
$699.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.33 Rating Score
Upside/​Downside
56.3% Upside
$12.80 Price Target
Short Interest
Bearish
4.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.94mentions of CymaBay Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.22) to ($1.07) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

256th out of 1,049 stocks

Pharmaceutical Preparations Industry

123rd out of 514 stocks

See Top Rated MarketRank™ Stocks Here

CBAY stock logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Stock News Headlines

January 30, 2023 | finance.yahoo.com
CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 24, 2023 | americanbankingnews.com
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Short Interest Update
January 30, 2023 | Investing Trends (Ad)
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
January 24, 2023 | americanbankingnews.com
Brokerages Set CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Target Price at $11.25
January 17, 2023 | finance.yahoo.com
Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength
January 9, 2023 | markets.businessinsider.com
CymaBay, Kaken To Develop And Commercialize Seladelpar In Japan For Primary Biliary Cholangitis
January 8, 2023 | finance.yahoo.com
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
November 23, 2022 | finance.yahoo.com
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) may have lost US$34m in value but insiders who invested last year have seen gains of around US$72k to date
January 30, 2023 | Investing Trends (Ad)
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
November 15, 2022 | seekingalpha.com
CymaBay Therapeutics, Inc. (CBAY) Q3 2022 Earnings Call Transcript
November 14, 2022 | finance.yahoo.com
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
November 8, 2022 | finance.yahoo.com
CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022
November 4, 2022 | finance.yahoo.com
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
November 3, 2022 | finance.yahoo.com
CymaBay Therapeutics to Present at Upcoming Investment Conferences
November 1, 2022 | finance.yahoo.com
CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
October 13, 2022 | finance.yahoo.com
Institutional investors own a significant stake of 50% in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
October 5, 2022 | marketwatch.com
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting(R) 2022
October 5, 2022 | finance.yahoo.com
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
October 3, 2022 | finance.yahoo.com
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
October 1, 2022 | reuters.com
Cymabay Therapeutics Inc
September 14, 2022 | baystreet.ca
CymaBay to Host Virtual Analyst Day Next Week
September 14, 2022 | finance.yahoo.com
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
August 30, 2022 | finance.yahoo.com
CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?
August 24, 2022 | finance.yahoo.com
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
August 16, 2022 | finance.yahoo.com
CymaBay Therapeutics Inc. (CBAY) Just Flashed Golden Cross Signal: Do You Buy?
August 13, 2022 | uk.investing.com
CymaBay Therapeutics Misses Q2 EPS by 2c
August 12, 2022 | finance.yahoo.com
CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CBAY Company Calendar

Last Earnings
11/14/2022
Today
1/30/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CBAY
CUSIP
N/A
CIK
1042074
Web
www.cymabay.com
Phone
(510) 293-8800
Fax
510-293-9090
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.80
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+55.0%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-90,000,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-110.63%
Return on Assets
-57.26%

Debt

Debt-to-Equity Ratio
1.43
Current Ratio
12.20
Quick Ratio
12.20

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.93 per share
Price / Book
4.28

Miscellaneous

Outstanding Shares
84,681,000
Free Float
79,939,000
Market Cap
$699.47 million
Optionable
Optionable
Beta
0.19

Key Executives

  • Sujal Shah
    President, Chief Executive Officer & Director
  • Daniel Menold
    Vice President-Finance
  • Charles A. McWherter
    President-Research & Development
  • Dennis D. KimDennis D. Kim
    Chief Medical Officer
  • Paul T. Quinlan
    Secretary & Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CBAY Stock - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CBAY shares.
View CBAY analyst ratings or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12-month price targets for CymaBay Therapeutics' shares. Their CBAY share price forecasts range from $8.00 to $19.00. On average, they predict the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price.
View analysts price targets for CBAY or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2023?

CymaBay Therapeutics' stock was trading at $6.27 at the start of the year. Since then, CBAY shares have increased by 24.4% and is now trading at $7.80.
View the best growth stocks for 2023 here.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our CBAY earnings forecast.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $7.80.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $660.50 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for the company is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 1/30/2023 by MarketBeat.com Staff